http://www.cnr.it/ontology/cnr/individuo/prodotto/ID179675

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy (Articolo in rivista)

Type

Label

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy (Articolo in rivista) (literal)

Anno

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

Alternative label

MARCO TUCCORI,a,d DANIELE FOCOSI,b CORRADO BLANDIZZI,a,d MATTEO PELOSINI,b SABRINA MONTAGNANI,a,d FABRIZIO MAGGI,c MAURO PISTELLO,c LUCA ANTONIOLI,a MATTEO FORNAI,a PASQUALE PEPE,e GIUSEPPE ROSSI,e MARIO PETRINIb (2010)
Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy
in The oncologist (Dayt. Ohio, Online); Alphamed Press, Durham (Stati Uniti d'America)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

MARCO TUCCORI,a,d DANIELE FOCOSI,b CORRADO BLANDIZZI,a,d MATTEO PELOSINI,b SABRINA MONTAGNANI,a,d FABRIZIO MAGGI,c MAURO PISTELLO,c LUCA ANTONIOLI,a MATTEO FORNAI,a PASQUALE PEPE,e GIUSEPPE ROSSI,e MARIO PETRINIb (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

aDivision of Pharmacology and Chemotherapy, Department of Internal Medicine, bDivision of Haematology, Department of Oncology, Transplantations and New Technologies in Medicine, and cVirology Section and Retrovirus Centre, Department of Experimental Pathology, University of Pisa, Pisa, Italy; dTuscan Regional Centre of Pharmacovigilance, Pisa, Italy; eInstitute of Clinical Physiology, Unit of Epidemiology and Biostatistics, National Research Council, Pisa, Italy (literal)

Titolo

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy (literal)

Abstract

Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1- 4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. (literal)

Editore